GlassScriptPhysician profile
Gurpreet S Sareen
NPI 1093253957
$1,886.82
in general payments reported to CMS, 2019-2025
19 companies · $593 in 2025
The $593 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $127 · 2021: $146 · 2022: $151 · 2024: $542 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.93 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $402.83 | 2022-2025 | Freestyle Libre 3, Diamondback Peripheral, Esprit |
| Janssen Pharmaceuticals, INC | $293.25 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.96 | 2020-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $207.67 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $179.70 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $138.38 | 2019-2021 | |
| Lilly USA, LLC | $80.26 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $54.56 | 2025 | Trelegy Ellipta |
| Amgen INC. | $47.40 | 2024 | Krystexxa |
| Verona Pharma, INC. | $39.49 | 2025 | Ohtuvayre |
| Neurocrine Biosciences, INC. | $30.86 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.19 | 2019 | |
| Intra-Sana Laboratories | $22.65 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Dexcom, INC. | $20.60 | 2024 | Dexcom G6 Transmitter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.23 | 2024 | Watchman Flx |
| Chiesi USA, INC. | $16.05 | 2020 | |
| Pfizer Pharmaceuticals LLC | $12.82 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Sareen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.